GC Biopharma Corp.
http://www.globalgreencross.com/eng/index.do
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GC Biopharma Corp.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around
Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.
Korea 2023 Review: R&D Potential Shines Through Despite Challenges
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Ceragem Medisys
- Green Cross LabCell
- Green Cross Corporation
- GC Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice